Skip to content

Gastroduodenal Full Thickness Resection Device Registry - gdFTRD® Registry

Gastroduodenal Full Thickness Resection Device Registry - gdFTRD® Registry

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07142902
Enrollment
306
Registered
2025-08-27
Start date
2025-08-31
Completion date
2030-08-31
Last updated
2025-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoma, Subepithelial Gastrointestinal Tumors

Keywords

gdFTRD, gastroduodenal full thickness resection, endoscopic full thickness resection, EFTR

Brief summary

Endoscopic full-thickness resection (EFTR) is a therapeutic option for the treatment of challenging lesions such as subepithelial tumors (SETs) and epithelial neoplasia extending deeper than the mucosa or associated with significant fibrosis. EFTR may offer a less invasive treatment alternative relative to surgical approaches in selected patients. The gastroduodenal FTRD System (gdFTRD System) is an instrument for endoscopic full-thickness resection or deep partial wall resection and diagnostic tissue acquisition through removal of suitable lesions in the stomach and duodenum. The prospectively generated data of the gdFTRD registry shall be used to evaluate the application of the gdFTRD in clinical routine, to verify the acceptability of already known risks and to identify unknown risks and complications.

Detailed description

The gdFTRD registry is a registry on cases completed with the gdFTRD System. The gdFTRD System is used for full-thickness resection but the procedure is not part of the study. Only data processing is conducted within the study. For data processing, an EDC system is used. There are no patient reported outcomes, only physician-entered data on baseline, intervention/procedure, complications/adverse events and follow-up visits. Automatic plausibility checks have been programmed for quality assurance. Furthermore, warnings and hints will be given on predefined entries not allowed or to double-check values out of normal ranges. No source data verification is planned but data management will check the entries for completeness. No coding according to MEDRA or similar systems is planned. As the procedure is not part of the study, every participating site must operate according to their own SOPs. The sponsor and CRO have SOPs in place for conducting a study. Furthermore, data protection requirements and all applicable regulations are followed. The sample size was calculated based results of peer-reviewed publications on the gdFTRD System. As only continuous and categorial variables will be assessed, no separate statistical analysis plan is planned. In case the collected data allows for exploratory post hoc subgroup analysis further tests can be done according to the descriptions in the protocol. Missing data will not be included in the analysis and shall not be imputed.

Interventions

OTHERData processing only, treatment is not part of the registry

Treatment with the gdFTRD is part of the clinical routine, the registry only comprises data processing after treatment.

Sponsors

novineon CRO GmbH
CollaboratorUNKNOWN
Ovesco Endoscopy AG
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients of legal age in whom the gdFTRD was used for treatment in the upper GI tract (stomach and duodenum) independently from the registry and * who gave informed consent to data processing

Exclusion criteria

* Patients aged under 18 years * Patients in whom the colonic FTRD, diagnostic FTRD or non-device assisted EFTR was used for treatment * Patients who did not give informed consent to data processing

Design outcomes

Primary

MeasureTime frameDescription
Technical successDirectly post-procedureTechnical success (i.e. target lesion reached and resected; macroscopically complete)

Secondary

MeasureTime frameDescription
Full thickness resectionUp to 14 days post-procedureFull-thickness resection (i.e. histologically confirmed full-thickness resection)
R0 resectionUp to 14 days post-procedureR0 resection (i.e. histologically complete lesion resection)
Rate of curative resection (in case of malignant tumors)Up to 14 days post-procedureRate of curative resection (in case of malignant tumors)

Other

MeasureTime frameDescription
Incidence of procedure-related adverse events (Safety)Intra-procedural and directly post-procedureTotal procedure-related adverse events
Incidence of surgery due to procedure-related adverse events (Safety)up to 2 weeks post-procedureSurgery due to a procedure-related adverse event
Incidence of post-interventional complications (Safety)up to 2 weeks post-procedurePost-interventional complications
Incidence of further procedure-related complications (Safety)up to 3 years post-procedureOther procedure-related complications

Countries

Germany

Contacts

Primary ContactBettina Stritzke
bettina.stritzke@ovesco.com+49 707196528-174
Backup ContactMarc O. Schurr, Prof. Dr.
marc.schurr@ovesco.com+49 707196528-121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026